$85.40
0.971.15%
Pre-Market: 8:52 AM EDT
15 minutes delayed
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
04/24/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.75 | $2.95 | $1.65 | $2.70B | $2.80B | $2.77B | Get Alert |
02/22/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.60 | $2.80 | $1.96 | $2.70B | $2.80B | $2.83B | Get Alert |
11/01/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.90 | $2.05 | $1.02 | $2.39B | $2.47B | $2.45B | Get Alert |
07/31/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.85 | $2.10 | $1.02 | $2.38B | $2.50B | $2.46B | Get Alert |
04/26/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $0.95 | $2.38B | $2.50B | $2.46B | Get Alert |
02/27/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $1.61 | $2.38B | $2.50B | $2.58B | Get Alert |
10/26/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.12B | Get Alert |
08/03/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.11B | Get Alert |
04/27/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.10B | Get Alert |
02/23/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.14B | Get Alert |
10/27/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.82B | $1.88B | $1.85B | Get Alert |
07/28/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.79B | $1.88B | $1.82B | Get Alert |
04/29/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.81B | Get Alert |
02/25/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.91B | Get Alert |
11/05/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.81B | $1.87B | $1.86B | Get Alert |
08/04/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.85B | $1.95B | $1.90B | Get Alert |
04/29/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.85B | $1.95B | $1.97B | Get Alert |
02/26/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.95B | $2.05B | $1.95B | Get Alert |
The last reported Earnings numbers were from April 24, 2024 for the full year 2024 and was for an earnings per share guidance in the range of $2.75 and $2.95 versus the estimated EPS of $1.65.
Browse guidance and forecast on all stocks.